Oppenheimer Cuts Soleno Therapeutics (NASDAQ:SLNO) Price Target to $80.00

Soleno Therapeutics (NASDAQ:SLNO) had its target price decreased by Oppenheimer from $110.00 to $80.00 in a research report sent to investors on Wednesday,Benzinga reports. Oppenheimer currently has an outperform rating on the stock.

A number of other equities research analysts also recently weighed in on SLNO. Wall Street Zen raised shares of Soleno Therapeutics from a “hold” rating to a “buy” rating in a research note on Saturday, March 14th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Soleno Therapeutics in a report on Thursday, January 22nd. HC Wainwright reduced their price target on Soleno Therapeutics from $120.00 to $100.00 and set a “buy” rating for the company in a research report on Wednesday, March 4th. Wolfe Research set a $60.00 target price on Soleno Therapeutics in a research report on Monday, January 12th. Finally, Zacks Research cut shares of Soleno Therapeutics from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, February 3rd. One research analyst has rated the stock with a Strong Buy rating, twelve have issued a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, Soleno Therapeutics has a consensus rating of “Moderate Buy” and an average price target of $104.54.

Soleno Therapeutics Trading Down 1.2%

Shares of SLNO stock opened at $33.22 on Wednesday. The firm has a fifty day moving average of $39.58 and a 200-day moving average of $49.97. The stock has a market cap of $1.71 billion, a price-to-earnings ratio of 144.44 and a beta of -3.16. Soleno Therapeutics has a 52-week low of $32.15 and a 52-week high of $90.32. The company has a debt-to-equity ratio of 0.11, a quick ratio of 5.55 and a current ratio of 5.80.

Soleno Therapeutics (NASDAQ:SLNO) last issued its quarterly earnings data on Wednesday, February 25th. The company reported $0.80 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.64 by $0.16. The company had revenue of $91.73 million for the quarter, compared to the consensus estimate of $88.55 million. On average, equities research analysts forecast that Soleno Therapeutics will post -3.72 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Soleno Therapeutics

A number of institutional investors and hedge funds have recently modified their holdings of the business. Janus Henderson Group PLC grew its stake in shares of Soleno Therapeutics by 18.5% in the 4th quarter. Janus Henderson Group PLC now owns 7,178,354 shares of the company’s stock valued at $332,302,000 after buying an additional 1,122,015 shares during the period. Wellington Management Group LLP boosted its stake in Soleno Therapeutics by 43.7% in the fourth quarter. Wellington Management Group LLP now owns 3,322,799 shares of the company’s stock valued at $153,846,000 after acquiring an additional 1,010,704 shares during the last quarter. Vanguard Group Inc. grew its stake in shares of Soleno Therapeutics by 9.0% during the 4th quarter. Vanguard Group Inc. now owns 3,060,361 shares of the company’s stock worth $141,695,000 after acquiring an additional 253,212 shares during the period. Avoro Capital Advisors LLC grew its stake in Soleno Therapeutics by 12.5% in the 4th quarter. Avoro Capital Advisors LLC now owns 2,900,000 shares of the company’s stock valued at $134,270,000 after buying an additional 322,223 shares in the last quarter. Finally, State Street Corp increased its position in shares of Soleno Therapeutics by 21.9% during the fourth quarter. State Street Corp now owns 2,649,626 shares of the company’s stock valued at $122,678,000 after buying an additional 476,590 shares during the period. 97.42% of the stock is currently owned by institutional investors.

Key Headlines Impacting Soleno Therapeutics

Here are the key news stories impacting Soleno Therapeutics this week:

• Neutral Sentiment: Multiple law firms and claim services are issuing investor alerts reminding shareholders of the May 5, 2026 lead‑plaintiff deadline and encouraging affected investors to come forward. These notices increase visibility of the litigation but are procedural in nature. SLNO INVESTOR NOTICE: Faruqi & Faruqi, LLP Reminds Soleno Therapeutics (SLNO) Investors of Securities Class Action Deadline on May 5, 2026
• Negative Sentiment: Several firms (Hagens Berman, Kessler Topaz, Pomerantz, Rosen, etc.) have confirmed or publicized securities‑fraud class actions alleging material misstatements/omissions about Soleno’s Phase 3 program and the November 2025 disclosures about DCCR/VYKAT XR launch disruptions. This raises the risk of costly litigation, management distraction, and potential settlements. Soleno Therapeutics (SLNO) Faces Securities Class Action Amid Hyperphagia Drug Launch Disruptions — Hagens Berman
• Negative Sentiment: An analyst update from Oppenheimer (reported in media coverage) lowered expectations for the VYKAT XR launch and 2026 sales, trimming the growth/valuation story for Soleno and increasing downside risk if launch execution and uptake remain weak. A Look At Soleno Therapeutics (SLNO) Valuation As Oppenheimer Updates Vykat XR Launch And 2026 Sales Outlook

Soleno Therapeutics Company Profile

Soleno Therapeutics, Inc is a clinical‐stage biopharmaceutical company focused on the development and commercialization of therapies for rare and orphan diseases. Headquartered in Redwood City, California, Soleno leverages a precision medicine approach to identify and advance small‐molecule treatments that address underlying genetic and metabolic dysfunctions. The company’s scientific strategy centers on repurposing and reformulating existing compounds to maximize therapeutic benefit in underserved patient populations.

The company’s lead candidate, diazoxide choline controlled release (DCCR), is being investigated for the treatment of Prader-Willi syndrome (PWS), a complex neurodevelopmental disorder characterized by insatiable appetite, hormonal imbalances and behavioral challenges.